Valeant Pharmaceuticals hasn't convinced buyers to return, that's what my charts say.
Shares are finally roaring back from big losses in 2014 and 2015.
Juno Therapeutics' chart, and fortune, is on the rise.
A quick-turning reversal pattern is all that is needed to set things in motion.

An Options Play in Eli Lilly Real Money Pro($)

I want to use a marriage of stock and ratio call spreads to create a juiced-up, covered-call approach.
Indicators driven by price and volume are not calling out for immediate purchase.
Buyers expect a dovish Fed and are still trying to put money to work.
Things were looking up and then today happened.
Why this level on CAH is so important, and what you need to know about it.
Keep your powder dry and see if MCK tries to makes a double bottom.

Columnist Conversations

I don't offer advice often out here in the open but reserve that for my chat room, webinars and blog articles....
BC is moving well today.  Shares are up over 3.5% on fairly heavy trade and are trading at new 2016 highs...
Markets taking the latest rejection of the status quo in Italy in stride as the reforms were expected to lose ...
Merck continues to retreat from November's failed breakout.  Back on 9th and 10th of last month the stock...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.